Federal contractor · NEWTON, MA

EXTEND BIOSCIENCES INC

No contract obligations recorded for EXTEND BIOSCIENCES INC in FY2026. It also received $839.5K in federal grants and other assistance in FY2026.

Obligations · FY2026
$0
New awards
0
Sole-source
—
Single offer
—
UEI
DZTKWESJQQ99
Small businessWoman-owned
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 161.6KFY2020

Top buying agencies

Obligations in FY2026.

No contract obligations recorded for EXTEND BIOSCIENCES INC in FY2026.

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

EXTEND BIOSCIENCES INC received $839.5K in federal assistance in FY2026, on 3 actions (1 new awards), −56% vs FY2025. Its largest program was 12.420 · Military Medical Research and Development ($839.5K).

Assistance · FY2026
$839.5K
New awards
1
Actions
3
Since FY2021
$6.6M

Assistance by fiscal year

  1. 2MFY2021
  2. 0FY2022
  3. 899.8KFY2023
  4. 999.6KFY2024
  5. 1.9MFY2025
  6. 839.5KFY2026

By type

  1. Grants$839.5K100%

Top programs

  1. 12.420 · Military Medical Research and Development$839.5K100%

Awarding agencies

  1. Defense Health Agency$839.5K100%
    Department of Defense

Largest awards

  1. LONG-ACTING PTH FOR HYPOPARATHYROIDISM - PROJECT SUMMARY HYPOPARATHYROIDISM IS A RARE DISEASE THAT RESULTS FROM A DEFICIENCY OR INABILITY…$2M
    93.847 · Diabetes, Digestive, and Kidney Diseases Extramural Research· National Institutes of Health· Project grant· Aug 29, 2024 – Aug 26, 2026· R44DK138647
  2. A PHASE 2 STUDY INVESTIGATING THE SAFETY, TOLERABILITY AND EFFICACY OF EXT608 IN ADULTS WITH HYPOPARATHYROIDISM (IND146180; OCTOBER 14…$1.8M
    93.103 · Food and Drug Administration Research· Food and Drug Administration· Project grant· Sep 20, 2023 – Jul 28, 2026· R01FD007824
  3. DEVELOPMENT OF A LONG-ACTING GHRELIN DERIVATIVE AS A NOVEL ALS THERAPEUTIC$839.5K
    12.420 · Military Medical Research and Development· Defense Health Agency· Project grant· Aug 19, 2026 – Aug 19, 2026· HT9425261E466

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.